LBA-4 Results from an expanded phase 1 trial of botensilimab (BOT), a multifunctional anti-CTLA-4, plus balstilimab (BAL; anti-PD-1) for metastatic heavily pretreated microsatellite stable colorectal cancer (MSS CRC)

Andrea J. Bullock, Marwan Fakih, Michael S. Gordon, Apostolia M. Tsimberidou, Anthony B. El-Khoueiry, Breelyn A. Wilky, A. Pimentel, Kim Margolin, Daruka Mahadevan, Ani Sarkis Balmanoukian, Rachel E. Sanborn, Gary K. Schwartz, Ghassan K. Abou‐Alfa, Bruno Bockorny, Justin C. Moser, Sunil Sharma, Joseph E. Grossman, Katherine Rosenthal, Steven O’Day, Heinz‐Josef Lenz, Benjamin L. Schlechter